Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet-Milin, Sylviane Ragot, Céline Bossard, Nathalie Nadal, Charles Herbaux, Benoit Tessoulin, Emmanuelle Tchernonog, Cédric Rossi, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Simon Rule

Blood (2021) 137 (7): 877–887.

https://doi.org/10.1182/blood.2020008727

Published: 2021

Includes: Supplemental data

Journal Articles

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Mary B. Callanan, PhD, Elizabeth Macintyre, PhD MD, Marie-Helene Delfau-Larue, MD PhD, Catherine Thieblemont, MD PhD, Lucie Oberic, MD, Emmanuel Gyan, MD PhD, Krimo Bouabdallah, MD, Rémy Gressin, MD, Gandhi Damaj, MD PhD, Olivier Casasnovas, MD, Vincent Ribrag, MD, Samuel Griolet, Bénédicte Burlet, Benjamin Tournier, PhD, Sylviane Ragot, M.Sc, Caroline Bodet-Milin, Olivier Hermine, Steven Le Gouill, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140457

Published: 2020

Journal Articles

Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study

Jean-Baptiste Alberge, Bastien Jamet, Clement Bailly, Cyrille Touzeau, Jonathan Cruard, Thomas Carlier, Caroline Bodet-Milin, Michel Cherel, Philippe Moreau, MD, Stephane Minvielle, Francoise Kraeber-Bodere

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-140235

Published: 2020

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Blood (2018) 132 (Supplement 1): 257.

https://doi.org/10.1182/blood-2018-99-111321

Published: 2018

Journal Articles

Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma

Louise Bouard, Caroline Bodet-Milin, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Clement Bailly, Alice Garnier, MD, Amandine Le Bourgeois, PhD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, Pierre Gallas, MD, Cyrille Touzeau, MD PhD, Thomas Gastinne, MD, Anne Lok, MD, Lucie Planche, Steven Le Gouill, MDPhD, Philippe Moreau, MDPhD, Francoise Kraeber-Bodere, Patrice Chevallier, MD

Blood (2017) 130 (Supplement 1): 3266.

https://doi.org/10.1182/blood.V130.Suppl_1.3266.3266

Published: 2017

Journal Articles

Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

Blood (2017) 130 (Supplement 1): 190.

https://doi.org/10.1182/blood.V130.Suppl_1.190.190

Published: 2017

Journal Articles

Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group

Caroline Bodet-Milin, Clement Bailly, Michel Meignan, Alina Beriollo-Riedinger, Rene-Olivier Casasnovas, MD, Anne Devillers, Thierry Lamy, PhD MD, Maria Santiago-Ribeiro, Emmanuel Gyan, MD PhD, Céline Gallazzini-Crépin, Remy Gressin, MD, Thomas Carlier, Francoise Kraeber-Bodéré, Olivier Hermine, Steven Le Gouill, MD PhD

Blood (2015) 126 (23): 335.

https://doi.org/10.1182/blood.V126.23.335.335

Published: 2015

Journal Articles

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2014) 124 (21): 3708.

https://doi.org/10.1182/blood.V124.21.3708.3708

Published: 2014

Journal Articles

Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT

Julien Dubreuil, Roch Houot, MD PhD, Steven Le Gouill, Christiane Mounier, MD, Stéphane Courby, MD, Caroline Dartigeas, MD, Krimo Bouabdallah, MD, Marie Pierre Moles, MD, Alexis Magda, Olivier Tournilhac, MD, Mario Ojeda Uribe, Jean Cyril Bourre, Caroline Bodet-Milin, MD, Jean-Philippe Vuillez, MD PhD, Remy Gressin, MD

Blood (2014) 124 (21): 3070.

https://doi.org/10.1182/blood.V124.21.3070.3070

Published: 2014

Journal Articles

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Patrice Chevallier, MD, PhD, Caroline bodet-Milin, MD, Nelly Robillard, Thomas Eugene, MD, Audrey Ménard, Claire Le Houerou, Thierry Guillaume, MD, Jacques Delaunay, MD, Martine Escoffre-Barbe, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD, Françoise kraeber-Bodere, MD

Blood (2013) 122 (21): 3910.

https://doi.org/10.1182/blood.V122.21.3910.3910

Published: 2013

Journal Articles

Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study

Steven Le Gouill, Mary Callanan, Elizabeth Macintyre, MD, PhD, marie-Hélène delfau-Larue, Caroline bodet-Milin, MD, Michel Meignan, MD, PhD, Anne Moreau, MD, Alexandra Travers-Glehen, Marie-christine Béné, Corinne Haouin, MD, Remy Gressin, MD, Rene-Olivier Casasnovas, MD, Vincent Ribrag, MD, Gandhi Damaj, MD, Emmanuel Gyan, MD, PhD, Lucie Oberic, Krimo Bouabdallah, MD, Catherine Thieblemont, MD, PhD, Olivier Hermine, MD, PhD

Blood (2012) 120 (21): 152.

https://doi.org/10.1182/blood.V120.21.152.152

Published: 2012

Journal Articles

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90 y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

Blood (2012) 120 (21): 906.

https://doi.org/10.1182/blood.V120.21.906.906

Published: 2012

Journal Articles

Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA

Thomas Gastinne, Pierre-yves Le roux, Caroline bodet-Milin, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Nadine Morineau, MD, Herve Maisonneuve, MD, Anne Moreau, Philippe Moreau, Jean-Luc Harousseau, Pierre-Yves Salaun, Françoise kraeber-Bodere, Steven Le Gouill

Blood (2010) 116 (21): 3889.

https://doi.org/10.1182/blood.V116.21.3889.3889

Published: 2010

Journal Articles

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

Blood (2010) 116 (21): 2875.

https://doi.org/10.1182/blood.V116.21.2875.2875

Published: 2010

Journal Articles

Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

Xavier Cahu, Caroline Bodet-Milin, Thomas Gastinne, Hervé Maisonneuve, Nadine Morineau, Gandhi Damaj, Philippe Solal-Celigny, Philippe Moreau, Henri Jardel, Philippe Moreau, Jean-Luc Harousseau, Françoise Kraeber-Bodéré, Steven Le Gouill, MD, PhD

Blood (2008) 112 (11): 2835.

https://doi.org/10.1182/blood.V112.11.2835.2835

Published: 2008

Journal Articles

Analysis of FDG PET Diffuse Bone Marrow Uptake in Staging of Hodgkin’s Disease: A Reflect of Disease Infiltration or Just Inflammation?.

Pierre Y Salaun, MD, Thomas Gastine, MD, Loic Campion, MD, Pierre Cambefort, MD, Caroline Bodet-Milin, MD, Anne Moreau, MD, Steven Le Gouil, MD, Jean-Luc Harousseau, Françoise Kraeber-Bodéré, MD, PhD

Blood (2008) 112 (11): 1456.

https://doi.org/10.1182/blood.V112.11.1456.1456

Published: 2008

Journal Articles

Prognosis Value of [ 18 f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma.

Virginie Roland, Caroline Bodet Milin, Anne Moreau, Thomas Gastinne, Beatrice Mahe, Viviane Dubruille, Hervé Maisonneuve, Nadine Morineau, Philippe Moreau, Henri Jardel, Lucie Planche, Philippe Moreau, Jean- Luc Harousseau, Françoise Kraeber bodere, Steven Le Gouill, MD, PhD

Blood (2008) 112 (11): 2177.

https://doi.org/10.1182/blood.V112.11.2177.2177

Published: 2008

Journal Articles

Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome.

Steven Le Gouill, MD, PhD, Caroline Bodet-Milin, MD, Françoise Kraeber-Bodere, MD, PhD, Anne Moreau, MD, Laurent Campion, Benoit Dupas, MD, Thomas Gastinne, MD, Philippe Moreau, MD, Jean-Luc Harousseau, MD

Blood (2007) 110 (11): 1390.

https://doi.org/10.1182/blood.V110.11.1390.1390

Published: 2007

NARROW

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Impact of Early Post-Transplant 5-Point Deauville Scale (18)F-FDG-PET Status on Survival Outcomes after Allogeneic Transplantation for Lymphoma

Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group

Phase 1 Dose-Escalation Study of 90 yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22 + B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT

BCR-ABL1 Molecular Remission After 90 y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22 + Ph + B-ALL: A Potential New Treatment Paradigm

Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90 y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA

Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients

Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

Analysis of FDG PET Diffuse Bone Marrow Uptake in Staging of Hodgkin’s Disease: A Reflect of Disease Infiltration or Just Inflammation?.

Prognosis Value of [ 18 f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma.

Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only